서브메뉴
검색
Identifying Blood-Based Biomarkers of Efficacy, Toxicity and Outcome in Early-Stage Breast Cancer
Identifying Blood-Based Biomarkers of Efficacy, Toxicity and Outcome in Early-Stage Breast Cancer
상세정보
- 자료유형
- 학위논문 서양
- 최종처리일시
- 20260202103148
- ISBN
- 9798280752023
- DDC
- 615
- 서명/저자
- Identifying Blood-Based Biomarkers of Efficacy, Toxicity and Outcome in Early-Stage Breast Cancer
- 발행사항
- [Sl] : University of California, San Francisco, 2025
- 발행사항
- Ann Arbor : ProQuest Dissertations & Theses, 2025
- 형태사항
- 100 p
- 주기사항
- Source: Dissertations Abstracts International, Volume: 86-12, Section: B.
- 주기사항
- Includes supplementary digital materials.
- 주기사항
- Advisor: Veer, Laura Van 'T;Kroetz, Deanna.
- 학위논문주기
- Thesis (Ph.D.)--University of California, San Francisco, 2025.
- 초록/해제
- 요약The emergence of blood-based biomarkers has transformed the landscape of precision oncology, offering minimally invasive tools to guide treatment decisions and monitor disease dynamics. This dissertation investigates the prognostic and predictive value of circulating tumor cells (CTCs), cell-free orphan non-coding RNAs (oncRNAs), and serum immune markers in early-stage breast cancer, leveraging the TIPPING and I-SPY2 clinical trial platforms.In Chapter 2, we evaluated CTCs in the TIPPING study, revealing that patients with invasive lobular carcinoma (ILC) have significantly higher CTC counts than those with invasive ductal carcinoma (IDC), even at early disease stages. These histology-specific differences were associated with worse outcomes and support the implementation of subtype-specific CTC thresholds for prognostication and therapeutic stratification.Chapter 3 focused on the development and validation of a continuous oncRNA risk score derived from circulating cfRNAs in the I-SPY2 trial. The score was predictive of distant recurrence-free survival (DRFS) and provided prognostic value independent of established clinicopathologic features, including Residual Cancer Burden (RCB), nodal status, and MammaPrint risk. These findings support the clinical utility of tumor-naive cfRNA assays for individualized recurrence risk assessment.In Chapter 4, we explored serum immune markers as early indicators of treatment response and immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors within I-SPY2. Specific cytokines and checkpoint molecules were associated with both pathologic complete response (pCR) and irAEs, underscoring their dual role in efficacy and safety monitoring.Together, these studies highlight the complementary roles of CTCs, cfRNA oncRNAs, and immune markers in capturing both tumor-intrinsic and host-mediated mechanisms. This dissertation contributes to the growing body of evidence supporting liquid biopsy as a powerful, real-time tool for precision monitoring in early-stage breast cancer. The findings have potential implications for treatment tailoring, clinical trial design, and risk-adapted therapy strategies. Further validation in larger, independent cohorts is warranted to support clinical implementation.
- 일반주제명
- Pharmaceutical sciences
- 일반주제명
- Oncology
- 일반주제명
- Bioinformatics
- 일반주제명
- Pharmacology
- 키워드
- Biomarkers
- 키워드
- Breast cancer
- 키워드
- Clinical trials
- 키워드
- Worse outcomes
- 키워드
- Response
- 키워드
- Toxicity
- 기타저자
- University of California, San Francisco Pharmaceutical Sciences and Pharmacogenomics
- 기본자료저록
- Dissertations Abstracts International. 86-12B.
- 전자적 위치 및 접속
- 로그인 후 원문을 볼 수 있습니다.
MARC
008260126s2025 us c eng d■001000017357209
■00520260202103148
■006m o d
■007cr#unu||||||||
■020 ▼a9798280752023
■035 ▼a(MiAaPQ)AAI31995978
■040 ▼aMiAaPQ▼cMiAaPQ
■0820 ▼a615
■1001 ▼aAlkhafaji, Silver.▼0(orcid)0000-0002-2248-1381
■24510▼aIdentifying Blood-Based Biomarkers of Efficacy, Toxicity and Outcome in Early-Stage Breast Cancer
■260 ▼a[Sl]▼bUniversity of California, San Francisco▼c2025
■260 1▼aAnn Arbor▼bProQuest Dissertations & Theses▼c2025
■300 ▼a100 p
■500 ▼aSource: Dissertations Abstracts International, Volume: 86-12, Section: B.
■500 ▼aIncludes supplementary digital materials.
■500 ▼aAdvisor: Veer, Laura Van 'T;Kroetz, Deanna.
■5021 ▼aThesis (Ph.D.)--University of California, San Francisco, 2025.
■520 ▼aThe emergence of blood-based biomarkers has transformed the landscape of precision oncology, offering minimally invasive tools to guide treatment decisions and monitor disease dynamics. This dissertation investigates the prognostic and predictive value of circulating tumor cells (CTCs), cell-free orphan non-coding RNAs (oncRNAs), and serum immune markers in early-stage breast cancer, leveraging the TIPPING and I-SPY2 clinical trial platforms.In Chapter 2, we evaluated CTCs in the TIPPING study, revealing that patients with invasive lobular carcinoma (ILC) have significantly higher CTC counts than those with invasive ductal carcinoma (IDC), even at early disease stages. These histology-specific differences were associated with worse outcomes and support the implementation of subtype-specific CTC thresholds for prognostication and therapeutic stratification.Chapter 3 focused on the development and validation of a continuous oncRNA risk score derived from circulating cfRNAs in the I-SPY2 trial. The score was predictive of distant recurrence-free survival (DRFS) and provided prognostic value independent of established clinicopathologic features, including Residual Cancer Burden (RCB), nodal status, and MammaPrint risk. These findings support the clinical utility of tumor-naive cfRNA assays for individualized recurrence risk assessment.In Chapter 4, we explored serum immune markers as early indicators of treatment response and immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors within I-SPY2. Specific cytokines and checkpoint molecules were associated with both pathologic complete response (pCR) and irAEs, underscoring their dual role in efficacy and safety monitoring.Together, these studies highlight the complementary roles of CTCs, cfRNA oncRNAs, and immune markers in capturing both tumor-intrinsic and host-mediated mechanisms. This dissertation contributes to the growing body of evidence supporting liquid biopsy as a powerful, real-time tool for precision monitoring in early-stage breast cancer. The findings have potential implications for treatment tailoring, clinical trial design, and risk-adapted therapy strategies. Further validation in larger, independent cohorts is warranted to support clinical implementation.
■590 ▼aSchool code: 0034.
■650 4▼aPharmaceutical sciences
■650 4▼aOncology
■650 4▼aBioinformatics
■650 4▼aPharmacology
■653 ▼aBiomarkers
■653 ▼aBreast cancer
■653 ▼aClinical trials
■653 ▼aWorse outcomes
■653 ▼aResponse
■653 ▼aToxicity
■690 ▼a0572
■690 ▼a0992
■690 ▼a0715
■690 ▼a0419
■71020▼aUniversity of California, San Francisco▼bPharmaceutical Sciences and Pharmacogenomics.
■7730 ▼tDissertations Abstracts International▼g86-12B.
■790 ▼a0034
■791 ▼aPh.D.
■792 ▼a2025
■793 ▼aEnglish
■85640▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T17357209▼nKERIS▼z이 자료의 원문은 한국교육학술정보원에서 제공합니다.
